Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(AstraZeneca (United States)), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Shirish M. Gadgeel(Chinese University of Hong Kong), Mark G. Kris(Memorial Sloan Kettering Cancer Center), Jeffrey Girshman(Memorial Sloan Kettering Cancer Center), Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Afsheen N. Iqbal(Memorial Sloan Kettering Cancer Center)
Cited by 413
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k